Home » Stocks » IONS

Ionis Pharmaceuticals, Inc. (IONS)

Stock Price: $52.40 USD -1.01 (-1.89%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 7.32B
Revenue (ttm) 729.26M
Net Income (ttm) -451.29M
Shares Out 139.61M
EPS (ttm) 0.52
PE Ratio 101.16
Forward PE 90.91
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $52.40
Previous Close $53.41
Change ($) -1.01
Change (%) -1.89%
Day's Open 53.49
Day's Range 51.64 - 53.84
Day's Volume 1,230,580
52-Week Range 39.32 - 64.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

Zacks Investment Research - 2 days ago

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 3 days ago

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over the past year to $0.81, which bea...

PRNewsWire - 3 days ago

CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "...

PRNewsWire - 1 week ago

CARLSBAD, Calif., Feb. 19, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtu...

Zacks Investment Research - 1 week ago

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 weeks ago

CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Tim...

Forbes - 1 month ago

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in...

Other stocks mentioned: NBIX, VERX
PRNewsWire - 1 month ago

CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clini...

PRNewsWire - 1 month ago

CARLSBAD, Calif., Jan. 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive ...

Forbes - 1 month ago

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over ...

Other stocks mentioned: ALKS, BMRN
PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Sta...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 8, 2020 /PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined...

Zacks Investment Research - 2 months ago

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual f...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients wi...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Ea...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical tria...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigationa...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce pl...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its inve...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancemen...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview...

Business Wire - 3 months ago

LONDON--(BUSINESS WIRE)--Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled a...

Business Wire - 3 months ago

BOSTON & CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Sy...

Zacks Investment Research - 3 months ago

Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.

Seeking Alpha - 3 months ago

Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q3 2020 Results - Earnings Call Transcript

The Motley Fool - 3 months ago

The main problem: a lackluster performance for Spinraza.

Zacks Investment Research - 3 months ago

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -144.44% and -15.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...

Benzinga - 3 months ago

  Shares of Ionis Pharmaceuticals (NASDAQ:IONS) moved higher by 1.6% in pre-market trading after the company reported Q3 results.

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 4, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights. "We...

PRNewsWire - 3 months ago

CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. ...

Other stocks mentioned: PFE
PRNewsWire - 3 months ago

BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award fo...

Zacks Investment Research - 3 months ago

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 4 months ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, HRTX, ILMN, RGNX, LGND
PRNewsWire - 4 months ago

CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with I...

PRNewsWire - 4 months ago

CARLSBAD, Calif., Oct. 21, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Tim...

Seeking Alpha - 4 months ago

Ionis With Akcea: Still A Bargain

Other stocks mentioned: AKCA
Forbes - 4 months ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, NBIX, ACAD, ARWR, BMRN
The Motley Fool - 4 months ago

Here's what it takes to justify the current valuation.

PRNewsWire - 4 months ago

CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that IONIS-PKK-LRx is being evaluated in an in...

PRNewsWire - 4 months ago

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-...

Zacks Investment Research - 4 months ago

The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.

PRNewsWire - 4 months ago

BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeut...

PRNewsWire - 4 months ago

CARLSBAD, Calif., Sept. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (F...

Zacks Investment Research - 5 months ago

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 5 months ago

CARLSBAD, Calif., Sept. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Other stocks mentioned: AKCA
The Motley Fool - 5 months ago

The biotech is being acquired by its largest shareholder.

Other stocks mentioned: AKCA
Newsfile Corp - 5 months ago

(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders ewsfilecorp.com...

Other stocks mentioned: AKCA

About IONS

Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (A... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 1991
CEO
Brett Monia
Employees
817
Stock Exchange
NASDAQ
Ticker Symbol
IONS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is 65.47, which is an increase of 24.94% from the latest price.

Price Target
$65.47
(24.94% upside)
Analyst Consensus: Buy